| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ENOV | Common stock, par value $.001 | -Sell | -$30,074 | -713 | -3.01% | $42.18 | 22,990 | Feb 25, 2022 | Direct | F1 |
| transaction | ENOV | Common stock, par value $.001 | +Grant/Award | $0 | +22,072 | +96.01% | $0.00 | 45,062 | Feb 25, 2022 | Direct | F2 |
| transaction | ENOV | Common stock, par value $.001 | -Sell | -$419,014 | -10,153 | -22.53% | $41.27 | 34,909 | Feb 28, 2022 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to meet tax obligations relating to the vesting and delivery of certain restricted stock units and performance-based restricted stock units ("PRSUs"). |
| F2 | Reflects the certification of the performance criteria for PRSUs previously awarded in 2019. For more details on the PRSUs, please refer to the "Outstanding Equity Awards at 2020 Fiscal Year-End" table on page 42 of Colfax Corporation's 2021 Proxy Statement as filed with the Securities and Exchange Commission on April 1, 2021. |